Skip to content

Friday, February 3, 2023

Latest:

Philosophy, an ancient practice with modern appeal? The role of “big” questions in medical decision-making
Sensitive, rapid tests help to ID estrogen-disrupting chemicals in the environment
Why women with heart issues are undertreated and have worse outcomes than men
Breakthrough epigenetic study can improve the power to predict disease risk
When visible meets invisible: the importance of psychological screening and intervention in pediatric dermatology

Baylor College of Medicine Blog Network

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

MAPK4

Targeting MAPK4 may offer a new therapeutic opportunity for TNBC

January 27, 2022January 27, 2022AKT, cancer therapy, MAPK4, PI3K, PI3K inhibitor, Research, triple-negative breast cancer

MAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.

New evidence supports a cancer-promoting role for enzyme MAPK6

December 6, 2021December 6, 2021cancer growth, MAPK4, MAPK6, mTOR inhibitors, Research

The findings suggest that therapies that interfere with MAPK6 activity may offer an effective cancer treatment approach.

Targeting MAPK4 emerges as a promising therapy for prostate cancer

February 23, 2021February 23, 2021Akt pathway, androgen receptor, cancer therapy, castration-resistant prostate cancer, MAPK4, Prostate Cancer, Research

Inhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.

From the Labs Image of the Month

From the Labs: Adult-born neurons made the cover

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2020 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951